What Is Ozempic—and What It’s Approved For
Active Ingredient: Semaglutide
Pharmaceutical Class: Glucagon-like peptide-1 receptor agonist (GLP-1 RA)
Primary Indication: Glycemic control in adults with type 2 diabetes mellitus (T2DM)
Ozempic is the brand name for a once-weekly injectable formulation of semaglutide, developed by Novo Nordisk. Semaglutide mimics the body’s naturally occurring GLP-1 hormone, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying. These effects collectively lower blood sugar levels and contribute to modest weight loss—an ancillary benefit in individuals with T2DM.
Regulatory Status
U.S. FDA: Approved in December 2017 as an adjunct to diet and exercise for adults with type 2 diabetes. Not approved for chronic weight management under the Ozempic label.
UK NHS/EU EMA: Authorized for type 2 diabetes; not prescribed for weight loss.
Weight-loss Indication (Separate Brand): The same active ingredient under the brand Wegovy (semaglutide 2.4 mg weekly) holds approval for chronic weight management in patients with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.
Because Ozempic’s label does not include obesity management, prescribing it solely to lose weight would constitute off-label use—something clinicians generally avoid without robust evidence or clear patient benefit outweighing risk.
